A report in Bloomberg cites a registration in the Chinese Clinical Trial Registry confirming that the nasal spray vaccine candidate developed by Xiamen University, Hong Kong University and Beijing Wantai Biological Pharmacy Enterprise is undergoing Phase I human testing.
Nasal spray vaccines have been developed for influenza and are often used for children and adults who seek alternatives to a needle injection and in this case would add another method for administering the much sought-after COVID-19 vaccine.
Bloomberg said the vaccine candidate is the 10th from China to reach the human testing phase. An NPR report also said some scientists have expressed hope that a vaccine sprayed in the nose would be better suited to stopping the spread of COVID-19 through the respiratory tracts.
The Bloomberg report said there are currently around 35 other candidates in the midst of human testing as they accelerate the effort to bring a vaccine to market as soon as possible. Earlier this week, one of the frontrunning vaccines developed by AstraZeneca (NYSE:AZN) and Oxford University had its trials voluntarily paused after an unexplained illness arose in one of the subjects.
Other vaccine candidates are being tested right now, having been developed by Moderna (NSDQ:MRNA), Johnson & Johnson (NYSE:JNJ), Novavax (NSDQ:NVAX) and more. AstraZeneca, Moderna, Johnson & Johnson, Novavax and five other drug companies all announced a pledge to ensure safety with a potential vaccine, likely in response to claims from President Trump that a vaccine is coming soon.
In a Labor Day address, Trump said “the faster, the better,” when it comes to getting a vaccine out there, suggesting that, while the hope remains that a vaccine will be approved by the end of the year, it may come as soon as October.